Published in TB and Outbreaks Week, June 27th, 2000
The research was reported in the May 31 edition of the Journal of the American Chemical Society.
This class of antibiotics faces threats from its inherent high toxicity and its susceptibility to chemical modifications that allow bacteria to resist the drug's effects.
Bacteria, which create the proteins they need to survive, are constantly evolving and mutating in ways that circumvent the activity of antibiotics. To get around this problem, the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.